|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Pfizer Inc. (PFE)'s Zoloft no Better Than Dummy Pill, Says Lawsuit
2/4/2013 7:42:27 AM
The maker of Zoloft (Sertraline hydrochloride), Pfizer Inc., is being sued in a consumer class action suit, filed in the United States District Court for the Northern District of California, San Jose Division, before Magistrate Judge Paul Singh Grewal, which alleges that the patients who took the antidepressant medication experienced no more benefit than they would have done on a placebo (dummy pill). Laura Plumlee, the plaintiff (a person who is suing) said that during the three years she took Zoloft, it did not help her. Her lawyer, R. Brent Wisner, says the FDA (Food and Drug Administration) should not have approved Zoloft because Pfizer had not published some clinical trials which demonstrated that the medication was not significantly different to a placebo. Baum Hedlund, Aristei & Goldman and Pendley Baudin & Baudin & Coffin filed the lawsuit on behalf of the Plaintiff and consumers throughout the USA and California. A placebo is a dummy drug, a substance with no active ingredient taken by some participants in a clinical trial to determine whether the target drug, in this case Zoloft, is more effective. Pfizer is accused of deceptively marketing Zoloft as a "highly effective treatment for depression", while knowing that the medication was virtually indistinguishable from a sugar pill at best.
|
|
|
|
|
|
|
|
|
|
|